Despite significant advancements in cardiovascular medicine, a troubling trend has emerged in the treatment of severe aortic stenosis (AS). A comprehensive analysis of Medicare data published this week in JAMA Cardiology reveals that while the use of Transcatheter Aortic Valve Implantation (TAVI)—also known as TAVR—has surged over the last decade, the proportion of female patients receiving this life-saving intervention is steadily declining.
The study, which spans a decade of clinical practice, highlights a stark reality: not only are women increasingly underrepresented in TAVI procedures, but they also face higher risks of periprocedural complications and early mortality compared to their male counterparts. This analysis invites a critical re-examination of how healthcare systems identify, refer, and treat women suffering from heart valve disease.
Main Facts: The Growing Disparity
The study, led by Dr. Johny Nicolas of the Icahn School of Medicine at Mount Sinai, investigated 314,123 Medicare fee-for-service beneficiaries who underwent TAVI between 2013 and 2022. The results paint a picture of a system that may be inadvertently—or systematically—failing to serve women with the same efficacy as men.
The data indicates that while the absolute number of procedures for both sexes has grown, the "gender share" of these procedures has shifted in favor of men. In 2013, women accounted for 47.6% of all TAVI procedures. By 2022, that figure had dropped to 43.6%.
This decline is particularly concerning because the prevalence of aortic stenosis is virtually identical between the sexes. When medical professionals observe that the disease burden is equal but the treatment rates are diverging, it suggests that external factors—ranging from clinical bias to diagnostic limitations—are at play.
A Decade of Change: The Chronology of TAVI Expansion
To understand the current crisis, one must look at the evolution of TAVI indications over the past ten years. TAVI was initially a niche procedure, reserved for the highest-risk patients who were deemed inoperable for traditional open-heart surgery.
- 2011: Initial FDA approval for high-risk and inoperable patients.
- 2013–2015: The "High-Risk" era. During this foundational period, TAVI was gaining traction, and the gender distribution remained relatively balanced.
- 2016: The procedure was approved for intermediate-risk patients. This expansion allowed a broader swath of the population to access the technology.
- 2019: The FDA extended approval to low-risk patients, cementing TAVI as a standard of care for the majority of patients with severe aortic stenosis.
As the procedure became more "mainstream," researchers hypothesized that access would become more equitable. Instead, the opposite occurred. As the eligibility criteria expanded to include healthier, lower-risk patients, the percentage of women treated actually shrank. The analysis suggests that as the threshold for surgery lowered, the medical community’s perception of who is an "ideal candidate" may have defaulted toward a male-centric model, leaving women behind.
Supporting Data: Complications and Outcomes
The JAMA Cardiology report provides a granular look at the clinical hurdles women face when they do undergo TAVI. The data suggests that anatomical differences play a significant role in the higher complication rates observed in female patients.
Periprocedural Risks
Women demonstrated a significantly higher risk of periprocedural death (2.5% vs. 2.2%) compared to men. Furthermore, vascular complications and bleeding events were markedly higher in women. Researchers point to the smaller vessel sizes typical of female patients as a primary driver for these complications. When the delivery sheaths used for the procedure are designed with male-average anatomy in mind, the risk of vascular injury in smaller, female arteries increases significantly.
The "Paradox" of Long-Term Survival
Interestingly, the study found that at six years, women actually experienced higher survival rates than men. However, this "survival advantage" is tempered by a higher burden of morbidity. Even if they survive the initial procedure, women are more likely to be hospitalized for heart failure, suffer an acute myocardial infarction (MI), or experience a stroke.
The requirement for a permanent pacemaker—a common secondary intervention following TAVI—was notably lower in women (16.9%) than in men (20.0%), which stands as one of the few positive clinical findings for the female cohort in this study.
Official Responses and Expert Perspectives
Dr. Johny Nicolas and his team emphasize that the "male disease" reputation of aortic stenosis is a major barrier to care.
"With aortic stenosis, the disease manifests differently, in terms of symptoms, in men and women," Dr. Nicolas explained in an interview with TCTMD. "Because it is perceived differently, the patients are referred for a procedure—whether that’s surgery or TAVI—differently. Historically, women have been perceived as high-risk and sometimes don’t undergo treatment or are undertreated with interventions."
The research team suggests that "clinical inertia"—the reluctance to push for intervention—may be exacerbated by the pressure of hospital and operator performance metrics. If a physician knows that women have a statistically higher risk of periprocedural complications, they may be less inclined to recommend the procedure, fearing that a negative outcome will negatively impact their professional record. This creates a vicious cycle where women are referred only when their disease is much further advanced, which in turn leads to the very poor outcomes that physicians fear.
Implications: The Path Toward Equitable Care
The findings of this study carry profound implications for the future of cardiology. If current trends continue, a significant portion of the female population will continue to suffer from the debilitating, life-shortening effects of untreated aortic stenosis.
Rethinking Diagnostic Criteria
One of the most provocative suggestions from the research team is the potential need for sex-specific diagnostic cutoffs. Currently, the medical criteria for diagnosing the severity of aortic stenosis are largely uniform. However, because women often present with smaller aortic valve areas and less calcification, their disease severity is frequently underestimated. By the time a woman meets the current "threshold" for a referral, she may have already suffered irreversible heart damage.
Innovation in Technology
The higher rates of bleeding and vascular complications in women demand a technological response. Manufacturers of TAVI valves and delivery systems must prioritize the development of smaller-profile sheaths and sex-specific hardware. If the tools are better suited to female anatomy, the risk profile of the procedure could change, effectively narrowing the gap in periprocedural safety.
Changing the Referral Pipeline
Perhaps the most difficult challenge is addressing the implicit bias in referral patterns. The medical community must engage in more aggressive outreach to ensure that primary care physicians and cardiologists are aware of the atypical symptoms women often present with.
"We think we’re having a lot of undiagnosed patients," Dr. Nicolas noted. Improving public and provider awareness that aortic stenosis is not a "man’s disease" is the first step toward correcting the demographic skew in the data.
Conclusion
The data from 2013 to 2022 serves as a wake-up call. While the medical field has celebrated the success of TAVI as a revolutionary treatment for heart disease, this study proves that the revolution has not been felt equally by all. The decline in female access to TAVI is not a reflection of a decline in the need for treatment, but rather a reflection of systemic shortcomings in how the disease is identified and managed in women.
As we look toward the next decade of cardiovascular care, the mandate is clear: clinicians, researchers, and device manufacturers must collaborate to ensure that the advancements of modern medicine are accessible to all patients, regardless of sex. Without a concerted effort to dismantle these barriers, the "gender gap" in cardiac care will remain one of the most stubborn and dangerous inequities in modern medicine.
